Literature DB >> 28213773

Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option.

Jérôme Clerc1, Frederik A Verburg2, Anca M Avram3, Luca Giovanella4, Elif Hindié5, David Taïeb6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28213773     DOI： 10.1007/s00259-017-3654-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  50 in total

1.  Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.

Authors:  Ewa Ruel; Samantha Thomas; Michaela Dinan; Jennifer M Perkins; Sanziana A Roman; Julie Ann Sosa
Journal:  J Clin Endocrinol Metab       Date:  2015-02-02       Impact factor: 5.958

2.  [Differentiated thyroid carcinoma--how to improve the long-term results? Twenty-five-year outcomes of 850 patients].

Authors:  Didier Melliere; Elif Hindie; Jean-Pierre Becquemin; Pascal Desgranges; Eric Allaire; Emile Geachan
Journal:  Bull Acad Natl Med       Date:  2006-01       Impact factor: 0.144

3.  Radioactive iodine activities for postsurgical thyroid ablation: the lower the better.

Authors:  Furio Pacini
Journal:  Eur Thyroid J       Date:  2013-01

Review 4.  Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review.

Authors:  Ralph Blumhardt; Ely A Wolin; William T Phillips; Umber A Salman; Ronald C Walker; Brendan C Stack; Darlene Metter
Journal:  Endocr Relat Cancer       Date:  2014-10-02       Impact factor: 5.678

5.  Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer.

Authors:  F Vaisman; A Shaha; S Fish; R Michael Tuttle
Journal:  Clin Endocrinol (Oxf)       Date:  2011-07       Impact factor: 3.478

6.  Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma.

Authors:  Edward B Silberstein
Journal:  J Nucl Med       Date:  2007-06-15       Impact factor: 10.057

7.  Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis?

Authors:  Elif Hindié; Didier Mellière; Françoise Lange; Iyad Hallaj; Claire de Labriolle-Vaylet; Christian Jeanguillaume; Jacques Lange; Léon Perlemuter; Serge Askienazy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-07       Impact factor: 9.236

8.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

9.  Prognostic value of microscopic lymph node involvement in patients with papillary thyroid cancer.

Authors:  Stéphane Bardet; Renaud Ciappuccini; Elske Quak; Jean-Pierre Rame; David Blanchard; Dominique de Raucourt; Emmanuel Babin; Jean-Jacques Michels; Dominique Vaur; Natacha Heutte
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

10.  Response to initial therapy of differentiated thyroid cancer predicts the long-term outcome better than classical risk stratification systems.

Authors:  Albert Cano-Palomares; Ignasi Castells; Ismael Capel; Maria Rosa Bella; Santi Barcons; Angel Serrano; Xavier Guirao; Mercedes Rigla
Journal:  Int J Endocrinol       Date:  2014-07-08       Impact factor: 3.257
View more
  5 in total

1.  Postoperative serum thyroglobulin and neck ultrasound to drive decisions about iodine-131 therapy in patients with differentiated thyroid carcinoma: an evidence-based strategy?

Authors:  Luca Giovanella; Anca M Avram; Jerome Clerc; Elif Hindié; David Taïeb; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-07-30       Impact factor: 9.236

2.  Survival of Patients with Thyroid Cancer in Yazd, Iran

Authors:  Hassan Ali Vahedian Ardakani; Mansour Moghimi; Mohammad Shayestehpour; Masoud Doosti; Shamsi Beigi Sharifabadi
Journal:  Asian Pac J Cancer Prev       Date:  2017-08-27

3.  Unexpected radioactive iodine accumulation on whole-body scan after I-131 ablation therapy for differentiated thyroid cancer.

Authors:  Shingo Iwano; Shinji Ito; Shinichiro Kamiya; Rintaro Ito; Katsuhiko Kato; Shinji Naganawa
Journal:  Nagoya J Med Sci       Date:  2020-05       Impact factor: 1.131

4.  Downregulation of miR-146b-3p Inhibits Proliferation and Migration and Modulates the Expression and Location of Sodium/Iodide Symporter in Dedifferentiated Thyroid Cancer by Potentially Targeting MUC20.

Authors:  Shasha Hou; Xiaorui Xie; Jing Zhao; Cailan Wu; Ning Li; Zhaowei Meng; Chunquan Cai; Jian Tan
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 6.244

5.  Radioiodine in Differentiated Thyroid Carcinoma: Do We Need Diagnostic Pre-Ablation Iodine-123 Scintigraphy to Optimize Treatment?

Authors:  Elizabeth J de Koster; Taban Sulaiman; Jaap F Hamming; Abbey Schepers; Marieke Snel; Floris H P van Velden; Lioe-Fee de Geus-Oei; Dennis Vriens
Journal:  Diagnostics (Basel)       Date:  2021-03-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.